Flightpath Biosciences Accelerates Clinical Pipeline with New Drug License and Unveils New Corporate Identity to Support Next Phase of Growth
Flightpath Biosciences, a clinical-stage biotechnology company focused on treating infection-associated complex diseases, today announced a major advancement with the licensing of its newest drug candidate, FP530 (Formibactin A), a peptide deformylase inhibitor rediscovered by co-founder Kim Lewis, PhD, a Flightpath scientific cofounder and Head of Northeastern University’s Antimicrobial Drug Discovery Center. This is the second license from Northeastern University for Flightpath, and a testament to the many years of success and dedicated efforts of Dr. Lewis and his lab. This action follows the company’s recent license of lolamicin, a selective, microbiome-sparing drug platform technology from the University of Illinois, highlighting Flightpath’s growing leadership in the anti-infectives space.
Flightpath Licenses the First Antibiotic that Selectively Kills Lyme Disease Spirochetes
Flightpath Biosciences, Inc, a biotechnology company advancing microbiome-sparing therapeutics and diagnostics for infectious diseases, licensed a developmental antibiotic FP-100 acting selectively against a range of spirochetal pathogens from Northeastern University.
